Mechanism of transplantation-associated bone loss

Pediatric Nephrology

Volumn 14, Issue 7, 2000, Pages 650-653

  Sprague, Stuart M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bone loss; Immunosuppressive agents; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; TACROLIMUS; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MASS; BONE NECROSIS; CONFERENCE PAPER; FRACTURE; GROWTH RETARDATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; RAT; VITAMIN D DEFICIENCY;

EID: 0034116769     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670000359     Document Type: Conference Paper

References (31)

1. Sunthanthiran M, Morris RE, Strom TB (1996) Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 28:159-172
2. Mattos AM de, Olyaei AJ, Bennett WM (1996) Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 28:631-667
3. Pirsch JD, Miller J, Deierhoi MH, et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977-983
4. Epstein S (1996) Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 11:1-7
5. Pichette V, Bonnardeaux A, Prudhomme L, et al (1996) Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 28:105-114
6. Grotz WH, Mundinger FA, Gugel B, et al (1994) Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58:912-915
7. Nisbeth U, Lindh E, Ljunghall S, et al (1994) Fracture frequency after kidney transplantation. Transplant Proc 26:1764
8. Chiu MY, Sprague SM, Bruce DS, et al (1998) Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 9:677-683
9. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al (1999) Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 14:456-463
10. Lukert BP, Raisz LG (1990) Glucocorticoid induced osteoporosis, pathogenesis and management. Ann Intern Med 112:352-364
11. Canalis E (1996) Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endo Metab 81:3441-3447
12. Julian BA, Laskow DA. Dubovsky J, et al (1991) Rapid loss of vertebral bone density after renal transplantation. N Engl J Med 1325:544-550
13. Horber FF, Casez JP, Steiger U, et al (1994) Changes in bone mass early after kidney transplantation. J Bone Miner Res 9:1-9
14. Kwan JTC, Almond MK, Evans K, Cunningham J (1992) Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 18:166-168
15. Sanchez CP, Salusky IB, Kuizon BD, et al (1998) Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53:1358-1364
16. Torres A, Machado M, Concepcion MT, et al (1996) Influence of vitamin D receptor genotype on bone mass after renal transplantation. Kidney Int 50:1726-1733
17. Stewart PJ, Green OC, Stern PH (1986) Cyclosporine A inhibits calcemic hormone-induced bone resorption in vitro. J Bone Miner Res 1:285-291
18. Klaushofer K, Hoffman O, Stewart PJ, et al (1987) Cyclosporine A inhibits bone resorption in cultured neonatal mouse calvaria. J Pharmacol Exp Ther 243:584-590
19. Stewart PJ, Stern PH (1989) Interaction of cyclosporine A and calcitonin on bone resorption in vitro. Horm Metab Res 21:194-197
20. Stewart PJ, Stern PH (1989) Cyclosporines - correlation of immunosuppressive activity and inhibition of bone resorption. Calcif Tissue Int 45:222-226
21. Chowdhury MH, Shen V, Dempster DW (1991) Effects of cyclosporine A on chick osteoclasts in vitro. Calcif Tissue Int 49:275-279
22. Orcel P, Denne MA, DeVernejoul MC (1991) Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 128:1638-1646
23. DelPozo E, Zapf J (1994) Skeletal growth and bone density as sensitive parameters in experimental arthritis: effect of cyclosporin A. Bone 15:625-628
24. Orcel P, Bielakoff J, Modrowski D, et al (1989) Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J Bone Miner Res 4:387-391
25. Movsowitz C, Epstein S, Fallon M, et al (1988) Cyclosporin A in vivo produces severe osteopenia in the rat. Effect of dose and duration of administration. Endocrinology 123:2571-2577
26. Movsowitz C, Epstein S, Ismail F, et al (1989) Cyclosporin A in the oophorectomized rat: unexplained severe bone resorption. J Bone Miner Res 4:393-398
27. 3 in the rat and mouse. Endocrinology 128:1369-1373
28. Katz, I, Li M, Joffe I, et al (1994) Influence of age on cyclosporin A induced alterations in the rat in vivo. J Bone Miner Res 9:59-67
29. Buchinsky FJ, Ma Y, Mann GN, et al (1996) T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 137:2278-2285
30. Bryer H, Isserow JA, Armstrong EC, et al (1995) Azathioprine alone is bone sparing and does not alter cyclosporin A induced bone loss in the rat. J Bone Miner Res 10:1191-1200
31. Joffe I, Katz I, Sehgal S, et al (1993) Lack of change of cancellous bone volume with short term use of the new immunosuppressant rapamycin in rats. Calcif Tissue Int 53:45-52